Login
$TVTX
$49.70 -$0.95 (1.88%) Live

$TVTX 8-K/A SEC Filings

Filed On Filing
01 May 2025 8-K/A: Results of Operations and Financial Condition

Submitted sNDA seeking full approval of FILSPARI® (sparsentan) for FSGS in March 2025

07 Sep 2023 8-K/A: Financial Statements and Exhibits

On August 31, 2023 (the “Closing Date”), Travere Therapeutics, Inc., (“Travere” or the “Company”) completed the sale of substantially all of the assets that are primarily related to the Company’s business of development, manufacture (inc...

17 Aug 2022 8-K/A: Departure/Election of Directors or Officers; Compensation

THIS EMPLOYMENT AGREEMENT (this “Agreement”) is effective as of September 1, 2022 (the “Effective Date”) and is entered into by and between Travere Therapeutics, Inc., a Delaware corporation (hereinafter the “Company”), and Christopher C...

18 Nov 2020 8-K/A: Other Events

As previously reported on October 22, 2020, Travere Therapeutics, Inc. (f/k/a “Retrophin, Inc.”) (the “Company”) entered into a Stock Purchase Agreement (the “Agreement”) with Orphan Technologies Limited (“Orphan”) and Citco Trustees (Ca...

18 Sep 2019 8-K/A: Departure/Election of Directors or Officers; Compensation

(d) As previously reported in the Current Report on Form 8-K filed by Retrophin, Inc. (the “Company”) on May 9, 2019 (the “Original 8-K”), the Company’s Board of Directors appointed Sandra Poole as a director on May 9, 2019, to be effect...

19 May 2017 8-K/A: Departure/Election of Directors or Officers; Compensation

(d) As previously reported in the Current Report on Form 8-K filed by Retrophin, Inc. (the “Company”) on March 27, 2017 (the “Original 8-K”), the Company’s Board of Directors appointed John A. Orwin as a director on March 23, 2017. At th...

19 May 2017 8-K/A: Departure/Election of Directors or Officers; Compensation

(d) As previously reported in the Current Report on Form 8-K filed by Retrophin, Inc. (the “Company”) on April 13, 2017 (the “Original 8-K”), the Company’s Board of Directors appointed Ron Squarer as a director on April 10, 2017. At the ...

11 Mar 2015 8-K/A: Financial Statements and Exhibits

The following unaudited pro forma combined condensed statement of operations is based on the separate historical statement of operations of Retrophin, Inc. (the “Company”), the Thiola® product line and Manchester Pharmaceuticals, LLC (“M...

14 Aug 2014 8-K/A: Financial Statements and Exhibits

On May 29, 2014, the Company entered into a license agreement with Mission Pharmacal Company (“Mission”), a privately-held healthcare medications and treatments provider, for the U.S. marketing rights to Thiola®. The license adds Thiola®...

12 Jun 2014 8-K/A: Financial Statements and Exhibits

On March 26, 2014 (the “Closing Date”), Retrophin Inc. (“Retrophin” or the “Company”) acquired 100% of the outstanding membership interest of Manchester Pharmaceuticals, LLC (“Manchester”). The acquisition was financed with capital raise...

10 Jun 2014 8-K/A: Financial Statements and Exhibits

The report accompanying these financial statements was issued by BDO USA, LLP, a Delaware limited liability partnership and the U.S. member of BDO International Limited, a UK company limited by guarantee.

07 Jan 2014 8-K/A: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets

This STOCK PURCHASE AGREEMENT, dated as of December 23, 2013 (the “Agreement”), is by and among Retrophin, Inc., a Delaware corporation (“Buyer”), Kyalin Biosciences Inc., a Delaware corporation (the “Company”), and the parties set forth...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support